Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

CLASS ACTION UPDATE for ARDX, ANVS and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 28, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ARDX Shareholders Click Here: https://www.zlk.com/pslra-1/ardelyx-inc-loss-submission-form?prid=19926&wire=1
ANVS Shareholders Click Here: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19926&wire=1
SAVA Shareholders Click Here: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19926&wire=1

* ADDITIONAL INFORMATION BELOW *

Ardelyx, Inc. (NASDAQ: ARDX)

ARDX Lawsuit on behalf of: investors who purchased August 6, 2020 - July 19, 2021
Lead Plaintiff Deadline : September 28, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ardelyx-inc-loss-submission-form?prid=19926&wire=1

According to the filed complaint, during the class period, Ardelyx, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.

Annovis Bio, Inc. (NYSE:ANVS)

ANVS Lawsuit on behalf of: investors who purchased May 21, 2021 - July 28, 2021
Lead Plaintiff Deadline : October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=19926&wire=1

According to the filed complaint, during the class period, Annovis Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Cassava Sciences, Inc. (NASDAQ:SAVA)

SAVA Lawsuit on behalf of: investors who purchased September 14, 2020 - August 27, 2021
Lead Plaintiff Deadline : October 26, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19926&wire=1

According to the filed complaint, during the class period, Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/665894/CLASS-ACTION-UPDATE-for-ARDX-ANVS-and-SAVA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.